Cantor Fitzgerald analyst Josh Schimmer also mentioned Gracell Biotechnologies and Autolus Therapeutics as stocks that were "obviously" down in connection with the FDA's announcement. Gracell was recently down 17% to $4.46 while Autolus declined 11% to $4.50. Schimmer said the FDA investigation is "Likely a Storm in A Tea Cup." The FDA lists several approved products in the category, such as Yescarta from Gilead Sciences. It said "the overall benefits of these products continue to outweigh their potential risks for their approved uses."

Source: Wall Street Journal November 28, 2023 20:19 UTC